secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110848
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine
--------------------------------------------------------------------------------

- Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.
- Cash $12.6M at Sep 30, plus $5.8M from Oct warrant exercises; runway into Q3 2026.
- EMA SAWP confirmed iopofosine I 131 may qualify for Conditional Marketing Approval in WM; submission planned 2026.
- Phase 1b of CLR 125 (Auger-emitter) for triple-negative breast cancer initiated; RPDD granted for iopofosine in pediatric high-grade glioma.
- Raised ~$12.7M in Q3; funds to advance TNBC study and EMA application.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925110848/0001104659-25-110848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925110848/tm2531151d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer